

APPENDIX 4E
Preliminary Final Report to the Australian Stock Exchange

Name of Entity	Paradigm Biopharmaceuticals Limited
ABN	(ABN 94 169 346 963)
Year Ended	30 June 2016
Previous Corresponding Reporting Period	01 July 2014 to 30 June 2015

1. Results for Announcement to the Market

		\$	\$ and % increase/(decrease) over previous corresponding period	
Revenue from continuing activities		1,394,161	1,386,830	18917%
(Loss) from continuing activities after tax attributable to members		(2,924,425)	1,359,120	86.83%
Net (loss) for the period attributable to members		(2,924,425)	1,359,120	86.83%
Dividends (distributions)	Amount per security		Franked amount per security	
Final Dividend	N/A		N/A	
Interim Dividend	N/A		N/A	
Record date for determining entitlements to the dividends (if any)		N/A		
Brief explanation of any of the figures reported above necessary to enable the figures to be understood: N/A				

2. Key ratios

	Current Period	Previous corresponding period
Basic earnings per ordinary security (cents per share)	(3.60) cents	(4.68) cents
Diluted earnings per ordinary security (cents per share)	(3.60) cents	(4.68) cents
Net tangible asset backing per ordinary security (cents per share)	3.70 cents	0.71 cents

3. Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	Xosoma Pty Ltd
Date control gained	07 Aug 2015
Profit / (loss) from ordinary activities after tax of the controlled entity since the date in the current period on which control was acquired.	(\$1,358)
Profit / (loss) from ordinary activities after tax of the controlled entity (or group of entities) for the whole of the previous corresponding period.	(\$1,358)

Xosoma Pty Ltd also acquired 100% of the issued shares in C4M Pharmaceuticals Pty Ltd. C4M Pharmaceuticals Pty Ltd contributed Nil profit to the controlled entity.

4. Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited	<input checked="checked" type="checkbox"/>	The accounts are in the process of being audited	<input type="checkbox"/>
If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification: N/A			

5. Attachments Forming Part of Appendix 4E

The Annual Report of Paradigm Biopharmaceuticals Limited for the year ended 30 June 2016 is attached.

6. Signed

Signed in accordance with a resolution of the Directors.



Signed _____

Date: 31 August 2016

Graeme Kaufman

Chairman